- Page 2: Essentials in Ophthalmology Medical
- Page 6: Editors Frank G. Holz RichardF.Spai
- Page 10: Foreword The series Essentials in O
- Page 14: Contents Chapter 1 Microperimetry i
- Page 18: 5.2.2.13 Uveitis and Pseudoendophth
- Page 22: 10.6.5 Standard of Care vs. Cortico
- Page 26: XVI Contributors Grazia Levi, MD II
- Page 30: Chapter 1 Microperimetry in Macular
- Page 34: locations, we developed more advanc
- Page 38: Meanwhile, a normative database has
- Page 42: tions in a group of normals. Ninety
- Page 46: contrast, patients with impending h
- Page 52: 12 Microperimetry in Macular Diseas
- Page 56: 14 Microperimetry in Macular Diseas
- Page 60: 16 Microperimetry in Macular Diseas
- Page 64: 18 Microperimetry in Macular Diseas
- Page 68: 20 Microperimetry in Macular Diseas
- Page 72: 22 New Developments in cSLO Fundus
- Page 76: 24 New Developments in cSLO Fundus
- Page 80: 26 New Developments in cSLO Fundus
- Page 84: 28 New Developments in cSLO Fundus
- Page 88: 30 New Developments in cSLO Fundus
- Page 92: 32 New Developments in cSLO Fundus
- Page 96: 34 New Developments in cSLO Fundus
- Page 100:
36 Genetics of Age-Related Macular
- Page 104:
38 Genetics of Age-Related Macular
- Page 108:
40 Genetics of Age-Related Macular
- Page 112:
42 Genetics of Age-Related Macular
- Page 116:
44 Genetics of Age-Related Macular
- Page 120:
46 Genetics of Age-Related Macular
- Page 124:
48 Genetics of Age-Related Macular
- Page 128:
50 Genetics of Age-Related Macular
- Page 132:
52 Genetics of Age-Related Macular
- Page 136:
54 Anti-VEGF Treatment for Age-Rela
- Page 140:
56 Anti-VEGF Treatment for Age-Rela
- Page 144:
58 Anti-VEGF Treatment for Age-Rela
- Page 148:
60 Anti-VEGF Treatment for Age-Rela
- Page 152:
62 Anti-VEGF Treatment for Age-Rela
- Page 156:
64 Anti-VEGF Treatment for Age-Rela
- Page 160:
66 Anti-VEGF Treatment for Age-Rela
- Page 164:
68 Intravitreal Injections: Techniq
- Page 168:
70 Intravitreal Injections: Techniq
- Page 172:
72 Intravitreal Injections: Techniq
- Page 176:
74 Intravitreal Injections: Techniq
- Page 180:
76 Intravitreal Injections: Techniq
- Page 184:
78 Intravitreal Injections: Techniq
- Page 188:
80 Intravitreal Injections: Techniq
- Page 192:
82 Intravitreal Injections: Techniq
- Page 196:
84 Intravitreal Injections: Techniq
- Page 200:
86 Intravitreal Injections: Techniq
- Page 204:
Chapter 6 Combination Therapies for
- Page 208:
the pre-existing vessel toward the
- Page 212:
where there is inadequate delivery
- Page 216:
cularization, possibly related to i
- Page 220:
cidence of acute treatment-related
- Page 224:
6.7 Conclusion Treatments for CNV a
- Page 228:
40. Holekamp NM, Bouck N, Volpert O
- Page 232:
86. Tsutsumi-Miyahara C, Sonoda KH,
- Page 236:
106 Nutritional Supplementation in
- Page 240:
108 Nutritional Supplementation in
- Page 244:
110 Nutritional Supplementation in
- Page 248:
Chapter 8 New Perspectives in Geogr
- Page 252:
are atrophic, but also the layers a
- Page 256:
from RPE LF [13]. With the advent o
- Page 260:
ophy progression [27, 55]. No signi
- Page 264:
phenotypic features of FAF abnormal
- Page 268:
When CNV develops in previously dia
- Page 272:
pattern of different degrees of ele
- Page 276:
12. De Jong PT, Klaver CC, Wolfs RC
- Page 280:
57. Sunness J, Applegate CA, Gonzal
- Page 284:
132 Diabetic Macular Edema: Current
- Page 288:
134 Diabetic Macular Edema: Current
- Page 292:
136 Diabetic Macular Edema: Current
- Page 296:
138 Diabetic Macular Edema: Current
- Page 300:
140 Diabetic Macular Edema: Current
- Page 304:
142 Diabetic Macular Edema: Current
- Page 308:
144 Diabetic Macular Edema: Current
- Page 312:
146 Diabetic Macular Edema: Current
- Page 316:
148 Treatment of Retinal Vein Occlu
- Page 320:
150 Treatment of Retinal Vein Occlu
- Page 324:
152 Treatment of Retinal Vein Occlu
- Page 328:
154 Treatment of Retinal Vein Occlu
- Page 332:
156 Treatment of Retinal Vein Occlu
- Page 336:
158 Treatment of Retinal Vein Occlu
- Page 340:
160 Treatment of Retinal Vein Occlu
- Page 344:
162 Treatment of Retinal Vein Occlu
- Page 348:
Chapter 11 New Perspectives in Star
- Page 352:
e formed by the accumulation of yel
- Page 356:
11.3 Imaging Studies 11.3.1 Fluores
- Page 360:
In patients with STGD areas of reti
- Page 364:
11.4 Electrophysiology and Psychoph
- Page 368:
and localized to the rim region of
- Page 372:
eturn to the outer segment of the p
- Page 376:
4. Beharry S, Zhong M, Molday RS (2
- Page 380:
56. Suter M et al (2000) Age-relate
- Page 384:
184 Idiopathic Macular Telangiectas
- Page 388:
186 Idiopathic Macular Telangiectas
- Page 392:
188 Idiopathic Macular Telangiectas
- Page 396:
190 Idiopathic Macular Telangiectas
- Page 400:
192 Idiopathic Macular Telangiectas
- Page 404:
194 Idiopathic Macular Telangiectas
- Page 408:
196 Idiopathic Macular Telangiectas
- Page 412:
Chapter 13 Artificial Vision Peter
- Page 416:
40-200 µm. Electrode materials are
- Page 420:
A crucial problem in epiretinal sti
- Page 424:
from the cat’s visual cortex or b
- Page 428:
9. Chowdhury V, Morley JW, Coroneo
- Page 432:
54. Wolff JG, Delacour J, Carpenter
- Page 436:
212 Subject Index bull’s eye 166,
- Page 440:
214 Subject Index hypertension 118,
- Page 444:
216 Subject Index reactive oxygen s